Syngene International FY26 profit falls 20% on margin hit

What Syngene reported for FY26

Syngene International reported weaker profitability in FY26 despite a modest rise in revenue, with management pointing to pressure from a single large biologics customer and higher operating costs. Revenue from operations increased 3% year-on-year to Rs 3,739 crore from Rs 3,642 crore. Operating EBITDA fell 12% to Rs 918 crore, leading to margin compression to 25% from 29% a year earlier. Profit after tax (before exceptional items) declined to Rs 380 crore. Reported profit after exceptional items stood at Rs 317 crore. The company said the results were in line with its revised full-year guidance, even as headline margins and profit moved lower.

Management’s explanation: one large biologics client

The company attributed the performance to the impact of its largest biologics customer. Peter Bains, Managing Director and CEO, said: 'Syngene's full-year revenue from operations grew 3%, and with an EBITDA margin of 25%, performance was in line with our revised full-year guidance. The overall numbers reflect the specific impact from a single large-molecule biologics client, with the underlying business showing steady momentum.' The same theme also appeared in the company’s Q3 commentary, where management cited the impact of a single product linked to a large-molecule biologics client. Outside that factor, Syngene said its underlying business showed steady progress and Research Services secured new programs. The company’s disclosures indicate that client concentration in biologics became a key driver of near-term volatility in earnings.

Additional costs from scaling up biologics manufacturing

Syngene linked part of the margin pressure to higher costs as it ramps up capacity. Chief Financial Officer Deepak Jain said the margin pressure reflects 'additional operating costs as we bring the new biologics manufacturing facility in India into operations.' The company also flagged cost increases tied to new facilities, including higher power and utility expenses. In Q3, it said other direct costs, primarily power utility expenses, increased 2% year-on-year due to new facilities at Bayview in the US and the biologics facility in Bangalore. Other expenses were up 5% year-on-year due to general business expenses, automation and digital initiatives, and a hedge loss of Rs 23.3 crore versus a hedge gain of Rs 1.7 crore in the same quarter a year earlier. These cost lines, combined with softer contribution from one biologics client, weighed on operating profitability.

Q4 FY26: revenue crosses Rs 1,000 crore, but margins ease

The fourth quarter reflected similar pressures even as sequential momentum improved. Q4 revenue rose 2% year-on-year to Rs 1,037 crore and grew 13% quarter-on-quarter. Operating EBITDA declined 12% to Rs 303 crore, with EBITDA margin at 29% compared to 34% a year earlier. Profit after tax (before exceptional items) dropped 16% to Rs 153 crore. Reported profit after exceptional items was Rs 148 crore. The quarter was notable because operating revenue crossed the Rs 1,000 crore threshold, but the year-on-year profitability comparison remained weak due to lower margins.

Q3 FY26: net profit slump and labour code-related exceptional charge

Syngene’s Q3 FY26 performance drew market attention after a steep fall in reported net profit. Consolidated net profit decreased 88.6% year-on-year to Rs 15 crore from Rs 131.01 crore in the corresponding period of the previous year. Revenue from operations fell 2.8% year-on-year to Rs 917.1 crore (versus Rs 943.7 crore in Q3 FY25) and was up 0.7% quarter-on-quarter from Rs 910.6 crore in Q2 FY26. The company reported an exceptional loss of Rs 76 crore during the quarter due to changes linked to the new labour code, and another disclosure cited an exceptional expense of Rs 70.6 crore (Labour Code impact). It also reported additional gratuity costs of Rs 65.8 crore on a standalone basis and Rs 70.6 crore on a consolidated basis. Profit after tax but before exceptional items stood at Rs 73 crore, down 44% year-on-year.

What the company said about Librela and the biologics product impact

In Q3, the company linked the revenue and profit decline to ongoing inventory correction related to Librela (bedinvetmab), described as a first-in-class monoclonal antibody used to treat osteoarthritis in dogs. Management also reiterated that performance was affected by a single product from one of its large-molecule biologics clients. At the same time, Syngene stated that outside this factor, its Research Services business secured new programs and delivered continued growth. The disclosures, taken together, highlight that the drag was not described as broad-based weakness across all operating segments. The company also noted that other income declined 16% compared with Q3 last year, mainly due to a one-off related to interest on income taxes received in the prior year that was absent in the current year.

Share price reaction and trading levels mentioned

Syngene International shares fell sharply after the Q3 results, with the stock dropping as much as 5.7% to Rs 559.10 on the NSE, the lowest level since April 5, 2023. The results were announced after market hours, and the stock was also reported to have ended a prior session down 1.4% at Rs 592.15 on the BSE. The reported market move tracked the scale of the Q3 profit decline and the effect of the exceptional labour code-related provision on net margins.

Key numbers snapshot

Market impact: what changed in profitability and why it matters

The FY26 picture shows a classic mismatch between revenue growth and profitability, where operating leverage moved in the wrong direction. With revenue up 3% but EBITDA down 12%, the margin decline from 29% to 25% became the key financial development of the year. The company’s explanations consistently pointed to two drivers: softer contribution from a single large biologics client, and incremental operating costs tied to bringing a new biologics manufacturing facility in India into operations. In Q3, the labour code-related exceptional charges further distorted reported profit, pulling net margin down sharply and pushing reported profit to Rs 15 crore even though profit before exceptional items was Rs 73 crore. The numbers underscore that investors are tracking both the operational drag from client-specific factors and the accounting impact from regulatory-driven, non-recurring provisions.

Conclusion

Syngene International ended FY26 with revenue growth but lower margins and profit, as the impact of a single large biologics client and the cost of ramping new biologics capacity weighed on performance. Q4 showed improved sequential momentum, while Q3 highlighted how exceptional labour code-related charges can sharply affect reported earnings. Management has framed the outcomes as consistent with revised guidance and emphasised steady momentum in the underlying business outside the biologics client impact. Future updates are likely to be watched for signs of stabilisation in the biologics program contribution and the cost profile as the new India biologics facility moves further into operations.